Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Pamela Balcazar
Institution:
United States Food and Drug Administration
Observed institution:
United States Food and Drug Administration
ORCID:
0009-0002-9910-1540
Observed ORCID:
0009-0002-9910-1540
OpenAlex ID:
A5050952478
U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer
2018
·
Harpreet Singh
, Amanda J. Walker
, et al.
·
Clinical Cancer Research
·
109
PDF
Dosage optimization in drug development: An FDA Project Optimus analysis of postmarketing requirements issued to repair the cracks.
2023
·
Brian Heiss
, Lili Pan
, et al.
·
Journal of Clinical Oncology
·
10
PDF
Adoption of decentralized trial elements in cancer clinical trials supporting FDA approvals during COVID-19.
2024
·
Timil Patel
, Amy Corneli
, et al.
·
Journal of Clinical Oncology
·
1
Data from Adoption of Decentralized Trial Elements in Cancer Clinical Trials Supporting FDA Approvals during COVID-19
2025
·
Timil H. Patel
, Amy Corneli
, et al.
Supplementary Data from Adoption of Decentralized Trial Elements in Cancer Clinical Trials Supporting FDA Approvals during COVID-19
2025
·
Timil H. Patel
, Amy Corneli
, et al.
Show more works
View as search
Works count:
5
Citation count:
120
H-index:
2
I10-index:
2
Year
Topic
Type